pindolol has been researched along with Lung Diseases in 2 studies
Pindolol: A moderately lipophilic beta blocker (ADRENERGIC BETA-ANTAGONISTS). It is non-cardioselective and has intrinsic sympathomimetic actions, but little membrane-stabilizing activity. (From Martindale, The Extra Pharmocopoeia, 30th ed, p638)
pindolol : A member of the class of indols which is the 2-hydroxy-3-(isopropylamino)propyl ether derivative of 1H-indol-4-ol.
Lung Diseases: Pathological processes involving any part of the LUNG.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (50.00) | 18.7374 |
1990's | 1 (50.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Dorow, P | 1 |
Weiss, T | 1 |
Felix, R | 1 |
Schmutzler, H | 1 |
Park, PG | 1 |
Merryman, J | 1 |
Orloff, M | 1 |
Schuller, HM | 1 |
2 other studies available for pindolol and Lung Diseases
Article | Year |
---|---|
The influence of propranolol, metoprolol, and mepindolol on mucociliary clearance in coronary heart disease patients without pulmonary disease.
Topics: Cilia; Coronary Disease; Female; Humans; Lung; Lung Diseases; Male; Metoprolol; Middle Aged; Mucous | 1984 |
Beta-adrenergic mitogenic signal transduction in peripheral lung adenocarcinoma: implications for individuals with preexisting chronic lung disease.
Topics: Adenocarcinoma; Cell Division; Colforsin; Cyclic AMP; Epinephrine; Humans; In Vitro Techniques; Iodo | 1995 |